Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GSK
stocks logo

GSK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
8.41B
+3.56%
0.608
+4.9%
7.81B
+3.92%
1.200
-0.3%
8.28B
+3.64%
1.271
+2.45%
Estimates Revision
The market is revising Upward the revenue expectations for GSK plc (GSK) for FY2025, with the revenue forecasts being adjusted by 0.25% over the past three months. During the same period, the stock price has changed by 19.93%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.25%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.26%
In Past 3 Month
Stock Price
Go Up
up Image
+19.93%
In Past 3 Month
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 48.570
sliders
Low
45.00
Averages
45.00
High
45.00
Current: 48.570
sliders
Low
45.00
Averages
45.00
High
45.00
Berenberg
Kerry Holford
Hold
maintain
2025-11-26
Reason
Berenberg
Kerry Holford
Price Target
2025-11-26
maintain
Hold
Reason
Berenberg analyst Kerry Holford raised the firm's price target on GSK to 1,660 GBp from 1,600 GBp and keeps a Hold rating on the shares.
BofA
Underperform -> Neutral
upgrade
2025-11-25
Reason
BofA
Price Target
2025-11-25
upgrade
Underperform -> Neutral
Reason
BofA upgraded GSK to Neutral from Underperform with a price target of 2,000 GBp, up from 1,700 GBp. GSK has a busy and "contentious" FY26 with two launches - Blenrep and Depemokimab - and three key pipeline events, the analyst tells investors. These events all help shape a "narrative of growth" in the specialty business potentially being sufficient to offset the HIV patent cliff, the analyst added.
Stifel
Hold
to
Buy
upgrade
$16 -> $40
2025-11-10
Reason
Stifel
Price Target
$16 -> $40
2025-11-10
upgrade
Hold
to
Buy
Reason
Stifel upgraded Cogent Biosciences (COGT) to Buy from Hold with a price target of $40, up from $16, after the company reported "overwhelmingly positive" results in the Phase 3 PEAK study of bezuclastinib plus sunitinib versus sunitinib alone in patients with imatinib-resistant or intolerant gastrointestinal stromal tumors. The combination arm PFS of 16.5 months is significantly higher than investor expectations of 11-12 months and this result also helps ward off competitive pressure from (GSK) GSK, which at CTOS reported a Phase 1 PFS of 15 months in second-line GIST, the analyst tells investors.
JPMorgan
Zain Ebrahim
Underweight
maintain
2025-11-07
Reason
JPMorgan
Zain Ebrahim
Price Target
2025-11-07
maintain
Underweight
Reason
JPMorgan analyst Zain Ebrahim raised the firm's price target on GSK to 1,500 GBp from 1,400 GBp and keeps an Underweight rating on the shares.
Guggenheim
Buy
downgrade
$4 -> $3
2025-10-28
Reason
Guggenheim
Price Target
$4 -> $3
2025-10-28
downgrade
Buy
Reason
Guggenheim lowered the firm's price target on Scynexis (SCYX) to $3 from $4 and keeps a Buy rating on the shares. The firm, which is updating its company model following the recent announcement that the company resolved their differences with GSK (GSK) on the restart of the MARIO trial for ibrexafungerp in invasive candidiasis, notes that its price target cut is mainly due to the loss of some of the potential milestone payments for ibrexafungerp.
Jefferies
Buy
initiated
£2,000
2025-10-27
Reason
Jefferies
Price Target
£2,000
2025-10-27
initiated
Buy
Reason
Jefferies assumed coverage of GSK with a Buy rating and 2,000 GBp price target. At a 30% discount, GSK "offers significant upside skew" and all that is required is for the new CEO to buy some time via an efficiency program given that there are green shoots within the pipeline and room for business development, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for GSK plc (GSK.N) is 0.00, compared to its 5-year average forward P/E of 9.91. For a more detailed relative valuation and DCF analysis to assess GSK plc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
9.91
Current PE
0.00
Overvalued PE
13.89
Undervalued PE
5.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
8.13
Current EV/EBITDA
7.53
Overvalued EV/EBITDA
9.97
Undervalued EV/EBITDA
6.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
2.07
Current PS
2.18
Overvalued PS
2.41
Undervalued PS
1.72
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

GSK News & Events

Events Timeline

(ET)
2025-12-04
10:20:00
FDA Plans to Reduce Drug Approval Trials, Shares of Icon and Others Drop
select
2025-12-04
09:50:00
FDA Plans to Simplify Medical Product Approvals to One Clinical Study
select
link
2025-12-02 (ET)
2025-12-02
11:30:00
FDA Drug Regulator Richard Pazdur to Retire at Month-End
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
01:34 AMSeekingAlpha
CDC Vaccine Panel Delays Vote on Hepatitis B Shots Due to Confusion

  • Delay in Voting: The CDC's Advisory Committee on Immunization Practices (ACIP) postponed voting on hepatitis B vaccination guidelines for newborns due to confusion over the wording of the questions, with a vote of 7-3 to delay until Friday.

  • Vaccination Recommendations: The proposed guidelines include recommendations for vaccination based on the mother's hepatitis B status, with specific instructions for children of mothers who test negative or positive for the virus, as well as those with unknown status.

  • Previous Delays: This delay marks the second time the ACIP has postponed voting on the hepatitis B vaccine, following a similar decision made in September.

  • Vaccine Options: The three hepatitis B vaccines approved in the U.S. are Merck's Recombivax HB, GSK's Engerix-B, and Dynavax Technologies' Heplisav-B.

[object Object]
Preview
7.0
12-04Benzinga
AstraZeneca and GSK Executives Requested to Assist in Overhauling UK Pricing Regulations - Report

  • New Drug-Pricing Initiative: The U.K. government is forming a panel with senior pharmaceutical executives from companies like AstraZeneca and GSK to explore alternatives to the expiring Voluntary Scheme for Branded Medicines Pricing and Access (VPAG).

  • Concerns from Pharmaceutical Companies: Manufacturers have expressed that the current VPAG structure limits investment, with some companies warning it may lead to reduced research and development in the U.K.

  • U.K.-U.S. Pharmaceutical Agreement: A recent agreement between the U.K. and the U.S. will see the U.K. pay 25% more for new U.S. medicines, while ensuring zero import taxes on U.K. pharmaceuticals for three years.

  • Merck's Investment Withdrawal: Merck & Co. announced the cancellation of a planned $1.36 billion research center in London, citing slow progress in life sciences investment and undervaluation of innovative medicines in the U.K.

[object Object]
Preview
4.5
12-02NASDAQ.COM
ETF Inflow Update: FENI, BTI, GSK, MNDY

  • FENI Stock Performance: FENI's share price is currently at $35.68, with a 52-week low of $26.2144 and a high of $36.3052, indicating a relatively strong position within its trading range.

  • Understanding ETFs: Exchange traded funds (ETFs) function similarly to stocks, where investors buy and sell "units" that can be created or destroyed based on demand, impacting the underlying assets.

  • Monitoring ETF Flows: Weekly analysis of shares outstanding helps identify ETFs with significant inflows or outflows, which can influence the buying or selling of the underlying holdings.

  • Author's Perspective: The opinions expressed in the article are those of the author and do not necessarily represent the views of Nasdaq, Inc.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is GSK plc (GSK) stock price today?

The current price of GSK is 48.57 USD — it has decreased -0.82 % in the last trading day.

arrow icon

What is GSK plc (GSK)'s business?

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

arrow icon

What is the price predicton of GSK Stock?

Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is GSK plc (GSK)'s revenue for the last quarter?

GSK plc revenue for the last quarter amounts to 11.52B USD, increased 10.62 % YoY.

arrow icon

What is GSK plc (GSK)'s earnings per share (EPS) for the last quarter?

GSK plc. EPS for the last quarter amounts to 0.66 USD, decreased -3400.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for GSK plc (GSK)'s fundamentals?

The market is revising Upward the revenue expectations for GSK plc (GSK) for FY2025, with the revenue forecasts being adjusted by 0.25% over the past three months. During the same period, the stock price has changed by 19.93%.
arrow icon

How many employees does GSK plc (GSK). have?

GSK plc (GSK) has 68629 emplpoyees as of December 05 2025.

arrow icon

What is GSK plc (GSK) market cap?

Today GSK has the market capitalization of 98.04B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free